Eczema Newswire (Page 10)

Eczema Newswire (Page 10)

Comprehensive Real-Time News Feed for Eczema. (Page 10)

Results 181 - 198 of 258 in Eczema

  1. BRIEF-Naturally Splendid Enterprises signs letter of intent to acquire packaging equipmentRead the original story w/Photo

    Sep 26, 2016 | Reuters

    ... drugmaker Sanofi and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, by next March.

    Comment?

  2. BRIEF-Arbitral Tribunal confirms Acorda's redemption right regarding Biotie sharesRead the original story w/Photo

    Sep 26, 2016 | Reuters

    LONDON, Sept 23 A spike in long-dated U.S., Japanese and German borrowing costs has rekindled memories of the 2013 "taper tantrum" for emerging markets, even though they appear far less vulnerable than during past such episodes. Sept 26 French drugmaker Sanofi and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, by next March.

    Comment?

  3. UPDATE 1-Aldi plans 300 mln stg UK store refresh as 2015 profit fallsRead the original story w/Photo

    Sep 26, 2016 | Reuters

    ... drugmaker Sanofi and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, by next March. LONDON, Sept 26 European stocks fell ...

    Comment?

  4. European shares slip as banking and energy stocks fallRead the original story w/Photo

    Sep 26, 2016 | Reuters

    ... drugmaker Sanofi and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, by next March. LONDON, Sept 26 The British arm of ...

    Comment?

  5. RPT-Investment Focus-Emerging markets better placed than 2013 to weather yield curve shiftRead the original story w/Photo

    Sep 26, 2016 | Reuters

    ... drugmaker Sanofi and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year

    Comment?

  6. Sanofi may win US approval of US$3 billion eczema drug by MarchRead the original story w/Photo

    Sep 25, 2016 | Channelnewsasia.com

    French drugmaker Sanofi and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential US$3 billion-a-year seller, by next March. French multinational pharmaceutical company SANOFI logo is seen at the headquarters in Paris, France, March 8, 2016.

    Comment?

  7. Sanofi may win U.S. approval of $3 bln eczema drug by MarchRead the original story w/Photo

    Mar 8, 2016 | Reuters

    Sanofi badly needs new products to make up for flagging sales in its diabetes business, where its top-seller Lantus faces growing competition. The two companies said on Monday that the U.S. Food and Drug Administration had accepted dupilumab for priority review for treating atopic dermatitis , a skin inflammation also known as atopic eczema, and set a target decision date of March 29. Dupilumab, an injectable antibody drug, is seen by investors as perhaps Sanofi's most promising pipeline medicine, since it has produced promising clinical results and could be first systemic therapy for severe AD.

    Comment?

  8. Allergan to buy three companies for combined $2.4 billionRead the original story w/Photo

    Sep 23, 2016 | Waco Tribune-Herald

    ... 27 years ago. The deal with Vitae Pharmaceuticals gives Allergan access to two products in development for treating eczema, a skin disease that causes itchy patches. "The acquisition of Vitae is a strategic investment for Allergan that adds strength ...

    Comment?

  9. Pediatric Atopic Dermatitis May Benefit From Early Immune InterventionRead the original story

    Sep 23, 2016 | PressReleasePoint

    Researchers for the first time have identified the skin phenotype of pediatric eczema or atopic dermatitis in infants, opening the door for personalized treatment approaches for young children with eczema. The study, led by researchers at the Icahn School of Medicine at Mount Sinai and Northwestern University's Feinberg School of Medicine, was published online today in the Journal of Allergy and Clinical Immunology .

    Comment?

  10. Skin phenotype of pediatric eczema opens door for personalized treatment of AD in infantsRead the original story w/Photo

    Sep 23, 2016 | Medical News

    Researchers for the first time have identified the skin phenotype of pediatric eczema or atopic dermatitis in infants, opening the door for personalized treatment approaches for young children with eczema. The study, led by researchers at the Icahn School of Medicine at Mount Sinai and Northwestern University's Feinberg School of Medicine, was published online today in the Journal of Allergy and Clinical Immunology.

    Comment?

  11. Why Pfizer's Stock Is a Big Gamble Right NowRead the original story w/Photo

    Sep 13, 2016 | The Motley Fool

    ... med from Pfizer's $5.5 billion deal to buy California-based Anacor Pharmaceuticals . The topical gel crisaborole, for eczema treatment, is currently under FDA review. Pfizer believes crisaborole could reach or exceed annual sales of $2 billion. A ...

    Comment?

  12. Why Pfizer's Stock Is a Big Gamble Right NowRead the original story w/Photo

    Sep 13, 2016 | Fox News

    ... med from Pfizer's $5.5 billion deal to buy California-based Anacor Pharmaceuticals . The topical gel crisaborole, for eczema treatment, is currently under FDA review. Pfizer believes crisaborole could reach or exceed annual sales of $2 billion. A ...

    Comment?

  13. Bayer (BAYRY) Stock Closed Lower, Exploring Sale of $1.1 Billion Dermatology DivisionRead the original story w/Photo

    Sep 8, 2016 | TheStreet.com

    Bayer is working with JPMorgan on the sale, which the company could choose to cancel at any point, the sources said. Bayer's dermatology unit includes products such as the eczema treatment Desonate and the rosacea medication Finacea.

    Comment?

  14. 3 Stocks That Turned $3,000 Into $30,000 or MoreRead the original story w/Photo

    Sep 1, 2016 | Fox News

    ... Regeneron may also soon secure FDA approval of two more drugs: the rheumatoid arthritis drug sarilumab and the eczema drug dupilumab. The FDA's decision date for sarilumab is Oct. 30, and dupilumab's application for approval was filed last quarter ...

    Comment?

  15. Cacao extract may improve atopic dermatitis-like symptoms, rodent studyRead the original story w/Photo

    Aug 24, 2016 | NutraIngredients-USA

    ... standard diet, and the final group was induced and given the immunosuppressant tacrolimus topically, common to treat eczema, with a standard diet. Theobroma cacao extract used was provided by Belgian chocolate giant Barry Callebaut. The beans were ...

    Comment?

  16. Cacao extract may improve atopic dermatitis-like symptoms, rodent studyRead the original story w/Photo

    Aug 24, 2016 | NutraIngredients

    ... standard diet, and the final group was induced and given the immunosuppressant tacrolimus topically, common to treat eczema, with a standard diet. Theobroma cacao extract used was provided by Belgian chocolate giant Barry Callebaut. The beans were ...

    Comment?

  17. Pfizer: Let's Stay TogetherRead the original story w/Photo

    Aug 24, 2016 | Bloomberg

    ... announced in May a $5.2 billion takeover of Anacor Pharmaceuticals, which gave it an experimental treatment for eczema. Then on Monday, Pfizer struck a $14 billion deal for Medivation, which has a blockbuster treatment for prostate cancer ...

    Comment?

  18. Pfizer buys cancer drug maker Medivation for $14 billionRead the original story w/Photo

    Aug 22, 2016 | KION 46

    ... since then, including a $5.2 billion purchase of Anacor, announced in May. Anacor's prime product is a treatment for eczema.

    Comment?